Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: Pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model

Journal of Biomedical Optics

Volumn 17, Issue 11, 2012, Pages

  Cekanova, Maria ^a   Uddin, Md Jashim ^b   Legendre, Alfred M ^a   Galyon, Gina ^a   Bartges, Joseph W ^a   Callens, Amanda ^a   Martin Jimenez, Tomas ^a   Marnett, Lawrence J ^b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

canine; cyclooxygenase 2; optical imaging; pharmacokinetic parameters; safety

Indexed keywords

ADVERSE EVENTS; BLOOD AND URINE SAMPLES; CANINE; CANINE MODELS; CLINICAL USE; COLORECTAL CANCER; CYCLOOXYGENASE 2; DATA SUPPORT; HIGH POTENTIAL; IMAGING AGENT; IN-VIVO; OPTICAL IMAGING; PHARMACOKINETIC EVALUATION; PHARMACOKINETIC PARAMETERS; PHARMACOKINETIC PROPERTIES; PHARMACOKINETIC STUDIES; PILOT STUDIES; SINGLE-DOSE; TIME POINTS; TIME-PERIODS; TUMOR DETECTION;

ACCIDENT PREVENTION; DISEASES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; OPTICAL IMAGE STORAGE; TUMORS;

PHARMACOKINETICS;

ANIMALIA; CANIS FAMILIARIS;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUORESCENT DYE; FLUOROCOXIB A; INDOLE DERIVATIVE; RHODAMINE;

ANIMAL; ANIMAL DISEASE; ANIMAL MODEL; ARTICLE; COLORECTAL TUMOR; DOG; DOG DISEASE; FEMALE; FLUORESCENCE IMAGING; INTRAVENOUS DRUG ADMINISTRATION; LIGHT RELATED PHENOMENA; MALE; METABOLISM; METHODOLOGY; PILOT STUDY;

ANIMALS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOG DISEASES; DOGS; FEMALE; FLUORESCENT DYES; INDOLES; INJECTIONS, INTRAVENOUS; MALE; MODELS, ANIMAL; OPTICAL IMAGING; OPTICAL PHENOMENA; PILOT PROJECTS; RHODAMINES;

EID: 84870576292     PISSN: 10833668     EISSN: 15602281     Source Type: Journal    
DOI: 10.1117/1.JBO.17.11.116002     Document Type: Article

References (55)

1. Smith W. L., Dewitt D. L., Garavito R. M., " Cyclooxygenases: structural, cellular, and molecular biology.," Annu. Rev. Biochem. 69, 145 - 182 (2000). ARBOAW 0066-4154 http://dx.doi.org/10.1146/annurev.biochem.69.1. 145
2. Marnett L. J., " The COXIB experience: a look in the rearview mirror.," Annu. Rev. Pharmacol. Toxicol. 49, 265 - 290 (2009). ARPTDI 0362-1642 http://dx.doi.org/10.1146/annurev.pharmtox.011008.145638
3. Abdalla S. I., et al., " Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.," Clin. Cancer Res. 10 (14), 4784 - 4792 (2004). CCREF4 1078-0432 http://dx.doi.org/10.1158/1078-0432.CCR-04-0015 (Pubitemid 38955531)
4. Cohen E. G., et al., " Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma.," Clin. Cancer Res. 9 (9), 3425 - 3430 (2003). CCREF4 1078-0432 (Pubitemid 37082739)
5. Dannenberg A. J., Subbaramaiah K., " Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.," Cancer Cell 4 (6), 431 - 436 (2003). CCELER 1042-2196 http://dx.doi.org/10.1016/S1535-6108(03)00310-6 (Pubitemid 38050040)
6. Eberhart C. E., et al., " Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.," Gastroenterology 107 (4), 1183 - 1188 (1994). GASTAB 0016-5085 (Pubitemid 24294584)
7. Fosslien E., " Molecular pathology of cyclooxygenase-2 in neoplasia.," Ann. Clin. Lab. Sci. 30 (1), 3 - 21 (2000). ACLSCP 0091-7370 (Pubitemid 30078300)
8. Goodwin J. S., Ceuppens J., " Regulation of the immune response by prostaglandins.," J. Clin. Immunol. 3 (4), 295 - 315 (1983). JCIMDO 0271-9142 http://dx.doi.org/10.1007/BF00915791 (Pubitemid 14223897)
9. Inoue H., et al., " Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element.," J. Biol. Chem. 270 (42), 24965 - 24971 (1995). JBCHA3 0021-9258 http://dx.doi.org/10.1074/jbc. 270.42.24818
10. Sheng H., et al., " Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells.," Cell Growth Differ. 8 (4), 463 - 470 (1997). CGDIE7 1044-9523 (Pubitemid 27273083)
11. Taketo M. M., " COX-2 and colon cancer.," Inflamm. Res. 47 (Suppl 2), S112 - 116 (1998). INREFB 1023-3830 http://dx.doi.org/10.1007/ s000110050295 (Pubitemid 28493278)
12. Tsujii M., et al., " Cyclooxygenase regulates angiogenesis induced by colon cancer cells.," Cell 93 (5), 705 - 716 (1998). CELLB5 0092-8674 http://dx.doi.org/10.1016/S0092-8674(00)81433-6 (Pubitemid 28257578)
13. Neufang G., et al., " Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin.," Proc. Natl. Acad. Sci. U. S. A. 98 (13), 7629 - 7634 (2001). PNASA6 0027-8424 http://dx.doi.org/10.1073/pnas.121574098 (Pubitemid 32567999)
14. Liu C. H., et al., " Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.," J. Biol. Chem. 276 (21), 18563 - 18569 (2001). JBCHA3 0021-9258 http://dx.doi.org/10.1074/jbc. M010787200
15. Oshima M., et al., " Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).," Cell 87 (5), 803 - 809 (1996). CELLB5 0092-8674 http://dx.doi.org/10.1016/S0092- 8674(00)81988-1 (Pubitemid 26404280)
16. Chulada P. C., et al., " Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.," Cancer Res. 60 (17), 4705 - 4708 (2000). CNREA8 0008-5472
17. Kuge Y., et al., " Synthesis and evaluation of radioiodinated cyclooxygenase-2 inhibitors as potential SPECT tracers for cyclooxygenase-2 expression.," Nucl. Med. Biol. 33 (1), 21 - 27 (2006). NMBIEO 0969-8051 http://dx.doi.org/10.1016/j.nucmedbio.2005.10.004 (Pubitemid 43184074)
18. Schuller H. M., et al., " Detection of overexpressed COX-2 in precancerous lesions of hamster pancreas and lungs by molecular imaging: implications for early diagnosis and prevention.," Chem. Med. Chem. 1 (6), 603 - 610 (2006). CHEMGX 1860-7179 http://dx.doi.org/10.1002/(ISSN)1860-7187 (Pubitemid 44105786)
19. Uddin M. J., et al., " Synthesis and evaluation of [123I]-indomethacin derivatives as COX-2 targeted imaging agents.," J. Labell. Compds Radiopharmaceut. 52 (9), 387 - 393 (2009). JLCRD4 1099-1344 http://dx.doi.org/10.1002/jlcr.v52:9
20. Uddin M. J., et al., " [I]-Celecoxib analogues as SPECT tracers of cyclooxygenase-2 in inflammation.," ACS Med. Chem. Lett. 2 (2), 160 - 164 (2011). AMCLCT 1948-5875 http://dx.doi.org/10.1021/ml100232q
21. Uddin M. J., et al., " Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.," Cancer Res. 70 (9), 3618 - 3627 (2010). CNREA8 0008-5472 http://dx.doi.org/10.1158/ 0008-5472.CAN-09-2664
22. Uddin M. J., Marnett L. J., " Synthesis of 5- and 6-carboxy-X-rhodamines.," Org. Lett. 10 (21), 4799 - 4801 (2008). ORLEF7 1523-7060 http://dx.doi.org/10.1021/ol801904k
23. Chopra A., et al., " Molecular Imaging and Contrast Agent Database (MICAD): evolution and progress.," Mol. Imag. Biol. 14 (1), 4 - 13 (2012). 1536-1632 http://dx.doi.org/10.1007/s11307-011-0521-3
24. Leung K., et al., " Essential parameters to consider for the characterization of optical imaging probes.," Nanomedicine (Lond) 7 (7), 1101 - 1107 (2012). 1743-5889 http://dx.doi.org/10.2217/nnm.12.79
25. Damiano J. S., et al., " Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.," Blood 93 (5), 1658 - 1667 (1999). BLOOAW 0006-4971 (Pubitemid 29102494)
26. Narita T., et al., " Nonsteroidal anti-inflammatory drugs induce hypermotilinemia and disturbance of interdigestive migrating contractions in instrumented dogs.," J. Vet. Pharmacol. Ther. 29 (6), 569 - 577 (2006). JVPTD9 1365-2885 http://dx.doi.org/10.1111/jvp.2006.29.issue-6 (Pubitemid 44684101)
27. Kalgutkar A. S., et al., " Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors.," J. Med. Chem. 43 (15), 2860 - 2870 (2000). JMCMAR 0022-2623 http://dx.doi.org/10.1021/jm000004e (Pubitemid 30599644)
28. Flower R. J., " The development of COX2 inhibitors.," Nat. Rev. Drug Discov. 2 (3), 179 - 191 (2003). NRDDAG 1474-1776 http://dx.doi.org/10. 1038/nrd1034 (Pubitemid 37361663)
29. Kuge Y., et al., " Synthesis and evaluation of a radioiodinated lumiracoxib derivative for the imaging of cyclooxygenase-2 expression.," Nucl. Med. Biol. 36 (8), 869 - 876 (2009). NMBIEO 0969-8051 http://dx.doi.org/ 10.1016/j.nucmedbio.2009.07.006
30. Krach L. E., et al., " Clinical tolerance and toxicity of intravenous baclofen: a pilot study in a canine model.," J. Pediatr. Rehabil. Med. 4 (2), 89 - 98 (2011). 1874-5393
31. Knudsen T., et al., " Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog.," Haemophilia 17 (6), 962 - 970 (2011). 1351-8216 http://dx.doi.org/10.1111/hae.2011.17.issue-6
32. Bartges J. W., et al., " Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.," Am. J. Vet. Res. 58 (5), 504 - 510 (1997). AJVRAH 0002-9645 (Pubitemid 27253769)
33. Paoloni M. C., et al., " Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.," PLoS One 5 (6), e11013 (2010). 1932-6203 http://dx.doi.org/10.1371/ journal.pone.0011013
34. Vane J. R., " Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.," Nat. New Biol. 231 (25), 232 - 235 (1971). http://dx.doi.org/10.1038/newbio231232a0
35. Gruet P., Seewald W., King J. N., " Evaluation of subcutaneous and oral administration of robenacoxib and meloxicam for the treatment of acute pain and inflammation associated with orthopedic surgery in dogs.," Am. J. Vet. Res. 72 (2), 184 - 193 (2011). AJVRAH 0002-9645 http://dx.doi.org/10.2460/ajvr. 72.2.184
36. Hart F. D., Boardman P. L., " Indomethacin: a new non-steroid anti-inflammatory agent.," Br. Med. J. 2 (5363), 965 - 970 (1963). BMJOAE 0007-1447 http://dx.doi.org/10.1136/bmj.2.5363.965
37. Brocks D. R., Jamali F., " Etodolac clinical pharmacokinetics., " Clin. Pharmacokinet 26 (4), 259 - 274 (1994). CPKNDH 0312-5963 http://dx.doi.org/10.2165/00003088-199426040-00003 (Pubitemid 24116205)
38. Davies N. M., et al., " Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.," Clin. Pharmacokinet 38 (3), 225 - 242 (2000). CPKNDH 0312-5963 http://dx.doi.org/10.2165/00003088-200038030-00003 (Pubitemid 30156623)
39. Davies N. M., Skjodt N. M., " Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.," Clin. Pharmacokinet 38 (5), 377 - 392 (2000). CPKNDH 0312-5963 http://dx.doi.org/10.2165/00003088-200038050-00001 (Pubitemid 30265259)
40. Takemoto J. K., et al., " Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.," Clin. Pharmacokinet 47 (11), 703 - 720 (2008). CPKNDH 0312-5963 http://dx.doi.org/10.2165/00003088-200847110-00002
41. Pasloske K., et al., " Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs.," J. Vet. Pharmacol. Ther. 22 (5), 314 - 319 (1999). JVPTD9 1365-2885 http://dx.doi.org/ 10.1046/j.1365-2885.1999.00225.x (Pubitemid 29520915)
42. King J. N., et al., " Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2.," J. Vet. Pharmacol. Ther. 34 (3), 298 - 311 (2011). JVPTD9 1365-2885 http://dx.doi.org/10.1111/jvp.2011.34.issue-3
43. Knapp D. W., Waters D. J., " Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans.," Mol. Med. Today 3 (1), 8 - 11 (1997). MMTOFK 1357-4310 http://dx.doi.org/10.1016/ S1357-4310(96)20031-0 (Pubitemid 28091878)
44. Spugnini E. P., et al., " COX-2 overexpression in canine tumors: potential therapeutic targets in oncology.," Histol. Histopathol 20 (4), 1309 - 1312 (2005). HIHIES 0213-3911 (Pubitemid 41489173)
45. Macewen E. G., " Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment.," Cancer Metastasis Rev. 9 (2), 125 - 136 (1990). CMRED4 0167-7659 http://dx.doi.org/10.1007/BF00046339 (Pubitemid 20311829)
46. Mohammed S. I., et al., " Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.," Cancer Res. 59 (22), 5647 - 5650 (1999). CNREA8 0008-5472
47. Pestili De Almeida E. M., et al., " Expression of cyclo-oxygenase-2 in naturally occurring squamous cell carcinomas in dogs.," J. Histochem. Cytochem. 49 (7), 867 - 875 (2001). JHCYAS 0022-1554 http://dx.doi.org/10.1177/ 002215540104900707
48. Mohammed S. I., et al., " Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.," Mol. Cancer Ther. 2 (2), 183 - 188 (2003).
49. Mohammed S. I., et al., " Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer.," Prostaglandins Leukot. Essent. Fatty Acids 70 (5), 479 - 483 (2004). PLEAEU 0952-3278 http://dx.doi.org/10.1016/j. plefa.2003.10.002 (Pubitemid 38482611)
50. Lee J. Y., et al., " Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma.," Res. Vet. Sci. 83 (2), 210 - 216 (2007). RVTSA9 0034-5288 http://dx.doi.org/10.1016/j.rvsc.2006.12.012
51. Dannenberg A. J., et al., " Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.," J. Clin. Oncol. 23 (2), 254 - 266 (2005). JCONDN 0732-183X http://dx.doi.org/10.1200/JCO. 2005.09.112 (Pubitemid 46206877)
52. Knapp D. W., et al., " Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors.," Cancer Chemother. Pharmacol. 29 (3), 214 - 218 (1992). CCPHDZ 0344-5704 http://dx.doi.org/10.1007/BF00686255
53. Knapp D. W., et al., " Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder.," J. Vet. Intern. Med. 8 (4), 273 - 278 (1994). JVIMEM
54. Schmidt B. R., et al., " Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs.," J. Am. Vet. Med. Assoc. 218 (11), 1783 - 1786 (2001). JAVMA4 0003-1488 http://dx.doi.org/10.2460/javma.2001. 218.issue-11 (Pubitemid 32520131)
55. Edelman M. J., et al., " Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203.," J. Clin. Oncol. 26 (6), 848 - 855 (2008). JCONDN 0732-183X http://dx.doi.org/10. 1200/JCO.2007.13.8081 (Pubitemid 351398075)